|
Patent landscape, scope, and claims: |
United States Patent 7,544,364 Scope, Claim Map, and US Patent Landscape for Cyclodextrin–Glycopeptide Antibiotic Compositions
Executive summary
- US Patent 7,544,364 claims a pharmaceutical composition combining a cyclodextrin with a glycopeptide antibiotic defined by a specific structural constraint on substituents R19, R20, and R5.
- Claim scope is anchored by (i) the glycopeptide substitution pattern (including a lipid substituent R20 with 10–40 carbons), and (ii) the specific pendant phosphonate-containing substituent recited at R5 as —CH2—NH—Ra—P(O)(OH)2 where Ra is alkylene.
- Dependent claims narrow to specific cyclodextrins (hydroxypropyl-β-cyclodextrin; sulfobutyl ether β-cyclodextrin), and to dosage form and loading (lyophilized powder; cyclodextrin about 1–40 wt%), plus salt forms including hydrochloride.
- The landscape risk is concentrated in later US filings and continuations covering: (a) additional glycopeptide variants that satisfy the R-group constraints, (b) alternative cyclodextrin hosts, (c) formulation and lyophilization process parameters, and (d) salt selection and stabilization.
What is the scope of US Patent 7,544,364 (cyclodextrin + glycopeptide antibiotic)?
Core claim 1 defines a two-component pharmaceutical composition
Claim 1 is a composition claim with two required elements:
- Cyclodextrin (component a)
- The claim does not require a specific cyclodextrin in claim 1. It only requires that the pharmaceutical composition comprises “a cyclodextrin.”
- Dependent claims add specific cyclodextrins, but claim 1 is broader.
- Glycopeptide antibiotic (component b) with strict substituent constraints
- The glycopeptide antibiotic is “having the formula” with at least the following constraints as you provided:
- R20 is a lipid substituent containing 10 to 40 carbon atoms, optionally containing heteroatoms selected from halo, oxygen, nitrogen, sulfur, and phosphorous.
- R19 is hydrogen.
- R5 is a substituent of the formula —CH2—NH—Ra—P(O)(OH)2.
- Ra is alkylene.
Immediate consequence for scope
- Any accused formulation must include a cyclodextrin and a glycopeptide antibiotic that satisfies these substitution rules. Changing the glycopeptide outside these constraints is a clean route to avoid literal claim 1 coverage, even if the formulation uses a cyclodextrin.
How do claims 1–7 narrow US 7,544,364 (cyclodextrin type, lyophilization, loading, salts)?
Independent claim 1
- Broad composition concept: “cyclodextrin + glycopeptide antibiotic” where glycopeptide meets R19/R20/R5 requirements.
Dependent claim 2
- Cyclodextrin = hydroxypropyl-β-cyclodextrin (HPβCD).
- This narrows the host but may still cover a wide range of glycopeptide structures that satisfy claim 1’s glycopeptide formula constraints.
Dependent claim 3
- Cyclodextrin = sulfobutyl ether β-cyclodextrin (SBEβCD).
- In practice, different cyclodextrins affect solubility and complexation strength. Claim 3 limits host identity but keeps glycopeptide scope broad.
Dependent claim 4
- Composition is a lyophilized powder.
- This adds a dosage form limitation. It matters for infringement posture because a non-lyophilized liquid or spray-dried form can be outside the literal terms of claim 4 (while potentially still implicated under other claims or doctrine-of-equivalents arguments, depending on the adjudicating court’s approach).
Dependent claim 5
- Cyclodextrin comprises about 1 to 40 wt% of the composition.
- This is a quantitative participation constraint that can be used as a design-around lever.
Dependent claim 6
- Glycopeptide is a pharmaceutically acceptable salt.
- Broad salts within the functional definition.
Dependent claim 7
- Glycopeptide is specifically a hydrochloride salt.
- This narrows salt species.
What glycopeptide structural features are required by US 7,544,364 (R20 lipid, R5 phosphonate, R19 hydrogen)?
Claim-anchoring structural predicates
The legal strength of 7,544,364 is tied to the specific structural elements recited in claim 1:
R20 lipid substituent: 10 to 40 carbon atoms
- The claim requires a lipid substituent containing 10–40 carbons.
- Optional heteroatoms allowed include halo, oxygen, nitrogen, sulfur, and phosphorous.
- This means the lipid can be hydrophobic and substituted, but still must fall in the carbon count window.
Design-around insight
- If a glycopeptide variant uses a lipid chain outside 10–40 carbons or uses a non-lipid substituent at the corresponding position, claim 1 likely does not read.
R19 must be hydrogen
- This excludes analogs where the corresponding position is substituted (e.g., hydroxylated, alkylated, glycosylated, or otherwise substituted derivatives).
Design-around insight
- Substitution at R19, even if other elements match, is a straightforward literal carve-out.
R5 must be —CH2—NH—Ra—P(O)(OH)2 with Ra alkylene
- This recites a phosphonic acid-containing side group: P(O)(OH)2.
- The linker —CH2—NH—Ra— requires an alkylene spacer.
Design-around insight
- Swapping phosphonate for another acidic group, eliminating the phosphonic acid, changing the linker architecture away from an “alkylene” spacer, or changing the —CH2—NH— connection is likely outside literal scope.
Which cyclodextrins are covered by US 7,544,364 (and what’s still left open)?
Claim 1 host is open-ended
- Claim 1 says “a cyclodextrin.” That term in claim construction typically includes β-cyclodextrin derivatives (hydroxylated and substituted). But the exact boundaries depend on how the patent itself and prosecution define “cyclodextrin.”
Dependent claims identify two examples
- Hydroxypropyl-β-cyclodextrin (claim 2)
- Sulfobutyl ether β-cyclodextrin (claim 3)
Net coverage effect
- Claim 1 supports a broader host theory than claims 2 and 3.
- If enforcement depends on proof, dependent claim examples allow narrower, cleaner infringement mapping where those specific cyclodextrins are used.
What formulation features are protected: lyophilized powder and cyclodextrin loading?
Lyophilized powder (claim 4)
- Claim 4 limits the composition to a lyophilized powder.
- A formulation delivered as a solution, suspension, reconstitutable liquid, or spray-dried powder can fall outside claim 4.
Cyclodextrin loading: about 1–40 wt% (claim 5)
- This provides a numeric infringement lever.
- “About” introduces tolerance, but the range still creates a quantifiable scope.
Risk posture
- If an accused product uses cyclodextrin outside that window, claim 5 may be avoidable.
- Claim 1 still exists without that loading limitation, so a host is not exempt solely by changing loading. A plaintiff would need to rely on claim 1 if claim 5 is avoided.
What salt forms are covered: pharmaceutically acceptable salts and hydrochloride?
Broad salt option (claim 6)
- Any pharmaceutically acceptable salt meets claim 6.
Specific salt (claim 7)
- Hydrochloride salt is specifically covered.
Net effect
- If a glycopeptide antibiotic is used as a different counterion salt, claim 6 and claim 7 become avoidable, but claim 1 still requires “a glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.” That means claim 1 can still read on the free base form, while claim 7 may be avoidable if the product uses a non-HCl salt and the glycopeptide is not in free base.
How strong is the patent estate for cyclodextrin–glycopeptide formulations (likely protection points and enforceability profile)?
What claim 1 does well
- It ties infringement to a definable chemical entity: the glycopeptide antibiotic substituent pattern.
- It creates a clear mapping for chemistry analysts and formulation teams: cyclodextrin identity plus glycopeptide structural compliance.
What limits enforcement
- Claim 1’s breadth is constrained by the glycopeptide substitution pattern. If the market’s commercial product uses a different lipid chain length, different R5 group, or substitution at R19, claim 1 may not read.
- Dependent claims limit further to specific cyclodextrins and dosage forms. Those are narrower enforcement targets but provide cleaner claim coverage when matched.
Practical enforceability profile
- Strongest for products using the same glycopeptide scaffold with the specified lipid and phosphonate substituent and formulated with the claimed cyclodextrins, especially HPβCD or SBEβCD, and especially in lyophilized powder formats.
What patent landscape surrounds US 7,544,364 (likely continuations, related composition claims, and design-around space)?
Because only the claim set is provided, the US-wide landscape can only be described at the level of claim-directional clusters that commonly expand from a composition core like 7,544,364.
1) Continuations covering additional cyclodextrins
- After claiming HPβCD and SBEβCD, subsequent filings often:
- add other substituted cyclodextrins (other ethers, mixed substitutions, different degrees of substitution),
- claim alternative host-to-guest molar ratio ranges or complexation conditions,
- include explicit process parameters for lyophilization.
2) Continuations covering alternative glycopeptide variants that still satisfy the R-group constraints
- The R20 window (10–40 carbons) and R5 phosphonate motif invite:
- additional lipid substituent embodiments within the carbon window,
- variants that keep R19 = H and retain the P(O)(OH)2 phosphonate side group architecture,
- counterion and salt form expansions (beyond HCl).
3) Formulation-specific patents
- Independent claim 1 protects the composition concept. Additional patents frequently focus on:
- excipient packages used with cyclodextrin–glycopeptide complexes,
- lyophilization cycle parameters (freezing/primary drying/secondary drying),
- stabilization against degradation.
4) Manufacturing and lyophilization-process barriers
- Even when formulation claims are avoided, process claims can persist. For a lyophilized product, drying and reconstitution stability are often protected separately.
How do generic or biosimilar entry risks arise from this claim structure?
If the entry keeps the same glycopeptide structure
- A generic that uses a substituted glycopeptide satisfying R19/R20/R5 can be exposed if it also uses a cyclodextrin and does not change dosage form or loading in a way that avoids dependent claims.
If the entry changes the glycopeptide scaffold
- Changing any of these features can defeat literal coverage of claim 1:
- lipid chain outside 10–40 carbons,
- substitution at R19 other than hydrogen,
- R5 not being the phosphonate-containing —CH2—NH—Ra—P(O)(OH)2 motif with Ra alkylene.
If the entry changes host, form, or loading
- Changing from HPβCD or SBEβCD can avoid claim 2 or claim 3, but not necessarily claim 1 if another cyclodextrin is still used.
- Avoiding lyophilized powder can avoid claim 4.
- Cyclodextrin weight percent outside 1–40 wt% can avoid claim 5, though claim 1 without the loading limitation can still matter.
What infringement mapping would look like (claim chart-ready checklist)?
For claim 1
- Identify the product’s glycopeptide antibiotic structure and verify:
- R19 = hydrogen
- R20 lipid substituent carbon count is 10–40 with allowed heteroatoms
- R5 contains the phosphonate motif —CH2—NH—Ra—P(O)(OH)2
- Confirm the product contains “a cyclodextrin.”
- Confirm both components are present in a single pharmaceutical composition.
For dependent claims
- Claim 2: host must be hydroxypropyl-β-cyclodextrin
- Claim 3: host must be sulfobutyl ether β-cyclodextrin
- Claim 4: product is specifically a lyophilized powder
- Claim 5: cyclodextrin at about 1–40 wt%
- Claim 6: glycopeptide is in a pharmaceutically acceptable salt form
- Claim 7: the salt is hydrochloride
Key takeaways
- US 7,544,364 protects a cyclodextrin-formulated glycopeptide antibiotic defined by R19 = H, R20 lipid 10–40 carbons, and R5 phosphonate side group —CH2—NH—Ra—P(O)(OH)2 (Ra alkylene).
- The strongest literal risk zone is a product using the same glycopeptide scaffold and formulated with a cyclodextrin, especially HPβCD or SBEβCD and often in a lyophilized powder form.
- The most reliable design-around levers are changing the glycopeptide substitution pattern (R19, R20 length, R5 phosphonate motif), then using host/formulation changes to defeat dependent claims.
FAQs
1) Does changing the cyclodextrin avoid infringement of US 7,544,364?
Not if any cyclodextrin is still used, because claim 1 requires only “a cyclodextrin.” Changing from HPβCD (claim 2) or SBEβCD (claim 3) can avoid those dependent claims.
2) Can a non-lyophilized product avoid claim 4?
Yes. Claim 4 is limited to “a lyophilized powder.” A different dosage form can avoid that dependent limitation, while claim 1 may still apply.
3) What is the most direct way to avoid claim 1 without removing cyclodextrin?
Change the glycopeptide so it no longer satisfies the structural constraints: R19 not hydrogen, R20 outside 10–40 carbons, or R5 not containing the specified phosphonate motif.
4) Is hydrochloride specifically required to infringe US 7,544,364?
No. Hydrochloride is only in dependent claim 7. Claim 1 covers glycopeptide antibiotic and its pharmaceutically acceptable salt forms.
5) How does cyclodextrin concentration affect claim coverage?
Claim 5 adds a quantitative loading requirement (about 1–40 wt%). Even if loading falls outside that range, claim 1 can still read if the composition contains a cyclodextrin and the glycopeptide meets the R-group structural constraints.
References
- United States Patent No. 7,544,364.
More… ↓
⤷ Start Trial
|
